These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 15461821)

  • 21. Analysis of a crossover clinical trial by permutation methods.
    Good P; Xie F
    Contemp Clin Trials; 2008 Jul; 29(4):565-8. PubMed ID: 18356118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of methods to analyse continuous data from pseudo cluster randomized trials.
    Teerenstra S; Moerbeek M; Melis RJ; Borm GF
    Stat Med; 2007 Sep; 26(22):4100-15. PubMed ID: 17328006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estimating sample size for a randomized clinical trial of lung cancer screening.
    Obuchowski NA
    Contemp Clin Trials; 2008 Jul; 29(4):466-77. PubMed ID: 18088564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Likelihood inference on the relative risk in split-cluster designs.
    Shoukri MM; Colak D; Donner A
    Clin Trials; 2011 Feb; 8(1):37-47. PubMed ID: 21335588
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficiency of the cross-over design: an empirical estimation.
    Garcia R; Benet M; Arnau C; Cobo E
    Stat Med; 2004 Dec; 23(24):3773-80. PubMed ID: 15580599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The 'number needed to sample' in primary care research. Comparison of two primary care sampling frames for chronic back pain.
    Smith BH; Hannaford PC; Elliott AM; Smith WC; Chambers WA
    Fam Pract; 2005 Apr; 22(2):205-14. PubMed ID: 15722397
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mixed noninferiority margin and statistical tests in active controlled trials.
    Tsou HH; Hsiao CF; Chow SC; Yue L; Xu Y; Lee S
    J Biopharm Stat; 2007; 17(2):339-57. PubMed ID: 17365228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How the type of risk reduction influences required sample sizes in randomised clinical trials.
    Bruynesteyn K; Wanders A; Landewé R; van der Heijde D
    Ann Rheum Dis; 2004 Nov; 63(11):1368-71. PubMed ID: 15231507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sample size calculations for 3-level cluster randomized trials.
    Teerenstra S; Moerbeek M; van Achterberg T; Pelzer BJ; Borm GF
    Clin Trials; 2008; 5(5):486-95. PubMed ID: 18827041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adaptive extensions of a two-stage group sequential procedure for testing primary and secondary endpoints (I): unknown correlation between the endpoints.
    Tamhane AC; Wu Y; Mehta CR
    Stat Med; 2012 Aug; 31(19):2027-40. PubMed ID: 22729929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How many do I need? Basic principles of sample size estimation.
    Devane D; Begley CM; Clarke M
    J Adv Nurs; 2004 Aug; 47(3):297-302. PubMed ID: 15238124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Power and sample size computations in simultaneous tests for non-inferiority based on relative margins.
    Dilba G; Bretz F; Hothorn LA; Guiard V
    Stat Med; 2006 Apr; 25(7):1131-47. PubMed ID: 16217842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimal sample allocation in clinical trials designed to investigate relative risks.
    Eastwood BJ
    Stat Med; 1996 Dec; 15(23):2523-38. PubMed ID: 8961461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Individual allocation had an advantage over cluster randomization in statistical efficiency in some circumstances.
    Hewitt CE; Torgerson DJ; Miles JN
    J Clin Epidemiol; 2008 Oct; 61(10):1004-8. PubMed ID: 18411038
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials.
    Anderson GL; Kooperberg C; Geller N; Rossouw JE; Pettinger M; Prentice RL
    Clin Trials; 2007; 4(3):207-17. PubMed ID: 17715246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sample size determination for assessing equivalence based on proportion ratio under a randomized trial with non-compliance and missing outcomes.
    Lui KJ; Chang KC
    Stat Med; 2008 Jan; 27(1):47-67. PubMed ID: 17708514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improving the estimation of change from baseline in a continuous outcome measure in the clinical trial setting.
    Mayer-Hamblett N; Kronmal RA
    Contemp Clin Trials; 2005 Feb; 26(1):2-16. PubMed ID: 15837448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sample size formulae for trials comparing group and individual treatments in a multilevel model.
    Moerbeek M; Wong WK
    Stat Med; 2008 Jul; 27(15):2850-64. PubMed ID: 17960589
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extended follow-up and spatial analysis of the American Cancer Society study linking particulate air pollution and mortality.
    Krewski D; Jerrett M; Burnett RT; Ma R; Hughes E; Shi Y; Turner MC; Pope CA; Thurston G; Calle EE; Thun MJ; Beckerman B; DeLuca P; Finkelstein N; Ito K; Moore DK; Newbold KB; Ramsay T; Ross Z; Shin H; Tempalski B
    Res Rep Health Eff Inst; 2009 May; (140):5-114; discussion 115-36. PubMed ID: 19627030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sample size for testing difference between two proportions for the bilateral-sample design.
    Qiu SF; Tang NS; Tang ML; Pei YB
    J Biopharm Stat; 2009 Sep; 19(5):857-71. PubMed ID: 20183448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.